TOP LATEST FIVE BOSENTAN URBAN NEWS

6 The phosphodiesterase-5 inhibitor sildenafil is accredited for PAH in FC I–IV in the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies accredited to be used in PAH. As no oral agent has shown superiority there remains discussion regarding which need to be utilized